24/7 Market News Snapshot 23 May, 2025 – Tiziana Life Sciences Ltd. Common Shares (NASDAQ:TLSA)

May 23, 2025

DENVER, Colo., 23 May, 2025 (www.247marketnews.com) – (NASDAQ:TLSA) are discussed in this article.
Tiziana Life Sciences Ltd. has recently demonstrated robust momentum in the market, with its stock price rising significantly to $1.531—a gain of approximately 11.75% from a previous close of $1.370. Opening at $1.44, the company has attracted substantial investor interest, as evidenced by a current trading volume of 568.74K shares. This surge in price reflects a positive sentiment surrounding the stock, likely influenced by the recent recognition of its innovative intranasal therapy, foralumab, in addressing moderate Alzheimer’s disease.

The breakthrough therapy garnered national attention following a feature on public radio, spotlighting its potential to revolutionize treatment for neurodegenerative disorders. Dr. Howard Weiner’s interview emphasized the early positive results observed in patients, notably through the experience of Joe Walsh. Walsh and his wife, Karen, shared his remarkable response to foralumab, with Dr. Weiner acknowledging an unprecedented reduction in brain inflammation. His comment, “I’ve never seen anything like this… This is something special,” epitomizes the therapy’s promise.

Intranasal foralumab is designed to enhance the immune response in the brain and focus on inflammation, a critical aspect in the progression of Alzheimer’s. As traditional treatments often fall short, this innovative approach provides hope for improved quality of life and engagement among affected patients. The positive testimonials from participants suggest a potential shift in treatment outcomes for those grappling with this debilitating condition.

As Tiziana advances its clinical journey, it firmly positions itself at the forefront of developing unique therapies. With foralumab being the only fully human anti-CD3 monoclonal antibody currently in clinical development, the company exemplifies a commitment to pioneering effective and safe treatment modalities for neuroinflammatory diseases. This advancement not only underscores Tiziana’s innovative capabilities but also represents a significant leap in Alzheimer’s research, potentially influencing future therapeutic strategies in this complex field.

Related news for (TLSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.